PTGER2抗体;PTGER2 Antibody—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse liver tissue, Mouse lung tissue, Primary antibody: P12076(PTGER2 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P12076(PTGER2 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P12076(PTGER2 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

PTGER2 (Prostaglandin E Receptor 2) is a G protein-coupled receptor that binds prostaglandin E2 (PGE2), a lipid mediator involved in inflammation, pain perception, and fever. It plays a key role in modulating immune responses, vascular function, and tissue homeostasis by activating intracellular signaling pathways like cAMP and calcium mobilization. PTGER2 is expressed in various tissues, including the immune system, gastrointestinal tract, and reproductive organs, and is implicated in pathologies such as cancer progression, cardiovascular diseases, and chronic inflammatory conditions (e.g., arthritis, colitis).

PTGER2 antibodies are essential tools for studying receptor expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and flow cytometry to quantify PTGER2 levels in cell lines, tissues, or biofluids. These antibodies aid in exploring PTGER2's role in disease mechanisms, drug-target interactions, and signaling crosstalk. Monoclonal antibodies are often preferred for specificity, while polyclonal versions may offer broader epitope recognition. Validation via knockout/knockdown models or blocking assays is critical to ensure reliability.

Research applications include investigating PTGER2's dual pro- and anti-inflammatory effects, its contribution to tumor microenvironment regulation, and its potential as a therapeutic target. Commercial PTGER2 antibodies are typically raised in hosts like rabbits or mice, with species reactivity spanning humans, mice, and rats. Their development supports both basic research and preclinical studies aiming to modulate PGE2 pathways for therapeutic benefit.